Associated Papers
Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study.
Wang R et al.
Cancer Research Communications, 2025
41217768 (PubMed )
Supplement: crc-25-0384_supplementary_table_s2_suppst2.xlsx › Supplementary_Table_2
Comprehensive genomic landscape of metastatic hormone-sensitive prostate cancer in the Chinese population.
Yang B et al.
World Journal of Surgical Oncology, 2025
41121095 (PubMed )
Supplement: 12957_2025_4049_MOESM3_ESM.xlsx › Somatic_mutations
Generation of prostate cancer assembloids modeling the patient-specific tumor microenvironment.
Lee J et al.
Plos Genetics, 2025
40163511 (PubMed )
Supplement: pgen.1011652.s005.xlsx › organoid_somatic_variants
Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity.
Wei Y et al.
Molecular Oncology, 2023
37584393 (PubMed )
Supplement: MOL2-17-2183-s002.xlsx › Table_S14
Standing in the canine precision medicine knowledge gap: Improving annotation of canine cancer genomic biomarkers through systematic comparative analysis of human cancer mutations in COSMIC.
Sakthikumar S et al.
Veterinary and Comparative Oncology, 2023
37248814 (PubMed )
Supplement: supplement_1.xlsx › Supp._Table_5
A genomic and epigenomic atlas of prostate cancer in Asian populations.
Li J et al.
Nature, 2020
Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data.
Camacho N et al.
Plos Genetics, 2017
FOXA1 mutations in hormone-dependent cancers.
Robinson JL et al.
Frontiers in Oncology, 2013
Select a paper to view details